Future trials should explore combination immunotherapies targeting both IL-1β and CB2 pathways in genetically stratified AD models, particularly those carrying risk alleles such as APOE4 or TREM2. This dual-target strategy may offer synergistic benefits by simultaneously modulating pro-inflammatory cytokines and enhancing microglial phagocytic function. Here, CNR2 is linked to Alzheimer disease.